Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ranvir Mangat"'
Autor:
D. Russell Wada, Hanbin Li, Angelica Quartino, Bert L. Lum, Whitney P. Kirschbrown, Jin Y. Jin, Amit Garg, Ranvir Mangat
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The aim of the study was to characterize the population pharmacokinetics (PK) of the intravenous formulation of trastuzumab, assess the impact of patient and pathological covariates on trastuzumab PK, and perform simulations to support dosing
Autor:
Ranvir Mangat, Adam Frymoyer, Rob ter Heine, Srijib Goswami, Lawrence J. Lesko, Ron J. Keizer
Publikováno v:
Cpt Pharmacometrics and Systems Pharmacology, 7, 785-787
Cpt Pharmacometrics and Systems Pharmacology, 7, 12, pp. 785-787
CPT: Pharmacometrics & Systems Pharmacology
Cpt Pharmacometrics and Systems Pharmacology, 7, 12, pp. 785-787
CPT: Pharmacometrics & Systems Pharmacology
Contains fulltext : 200252.pdf (Publisher’s version ) (Open Access) The development of model-informed precision dosing (MIPD) tools, especially in the form of native or web-based applications to be used at the bedside, has garnered marked attention
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eacc0ea63ccb35dfce3b79d65d1c267
http://hdl.handle.net/2066/200252
http://hdl.handle.net/2066/200252
Autor:
Devonie Waaka, Rod B. Ellis-Pegler, Nicola A. Cranshaw, Christian Schwabe, Dominik Heinzmann, Michaela Lehle, Bert L. Lum, Chris Wynne, Anne E. Dick, Ranvir Mangat, Chunze Li
Publikováno v:
Cancer Chemotherapy and Pharmacology. 72:1079-1087
To demonstrate pharmacokinetic (PK) comparability for a single dose of 600 mg subcutaneous (SC) trastuzumab, administered via a novel single-use injection device (SID) or handheld syringe in 119 randomized healthy male subjects. The co-primary PK end
Autor:
Anna Dmoszynska, Jianguo Zhi, Nancy Valente, Jing Li, Michael Wenger, Jennifer Visich, Tadeusz Robak, Ranvir Mangat, Amita Joshi
Publikováno v:
The Journal of Clinical Pharmacology. 52:1918-1926
This retrospective analysis characterizes rituximab population pharmacokinetics in combination with fludarabine and cyclophosphamide and its effect on fludarabine and cyclophosphamide disposition in chronic lymphocytic leukemia (CLL) patients. Rituxi
Autor:
Bert L. Lum, D. Russell Wada, Angelica Quartino, Hanbin Li, Whitney P. Kirschbrown, Amit Garg, Ranvir Mangat, Jin Y. Jin
Publikováno v:
Journal of Clinical Oncology. 35:2525-2525
2525 Background: The aim of this analysis was to develop a PPK model for IV trastuzumab (Herceptin), to assess the impact of patient covariates on PK, and perform simulations to support dosing recommendations. Methods: Serum trastuzumab concentration
Autor:
D.S. Waaka, C. Wynne, R.B. Ellis-Pegler, Dominik Heinzmann, Bert L. Lum, Ranvir Mangat, L.A. Herráez-Baranda, Michaela Lehle, Chunze Li, C. Schwabe
Publikováno v:
Annals of Oncology. 23:ix162-ix163
Background Intravenous (IV) trastuzumab, alone or with chemotherapy, is the standard of care for HER2-positive breast cancer and metastatic gastric cancer. The subcutaneous (SC) formulation of trastuzumab has shown non-inferiority vs. trastuzumab IV